{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:41:15Z","timestamp":1781624475131,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10787-025-02071-8","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T13:42:35Z","timestamp":1766410955000},"page":"1111-1121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long COVID: a review of mechanisms and treatment modalities"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9030-3383","authenticated-orcid":false,"given":"Mabel","family":"Yet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Sheung","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S. Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"2071_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121048","volume":"309","author":"SA Antar","year":"2022","unstructured":"Antar SA, Saleh MA, Al-Karmalawy AA (2022) Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and\/or anti-SARS-CoV-2. Life Sci 309:121048. https:\/\/doi.org\/10.1016\/j.lfs.2022.121048","journal-title":"Life Sci"},{"issue":"7821","key":"2071_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","volume":"584","author":"A Arvin","year":"2020","unstructured":"Arvin A, Fink K, Schmid M et al (2020) A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 584(7821):353\u2013363. https:\/\/doi.org\/10.1038\/s41586-020-2538-8","journal-title":"Nature"},{"key":"2071_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100122","volume":"6","author":"M Augustin","year":"2021","unstructured":"Augustin M, Schommers P, Stecher M et al (2021) Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Regional Health Europe 6:100122. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100122","journal-title":"Lancet Regional Health Europe"},{"issue":"4","key":"2071_CR4","doi-asserted-by":"publisher","first-page":"2402249","DOI":"10.1183\/13993003.02249-2024","volume":"65","author":"G Bermudo-Peloche","year":"2025","unstructured":"Bermudo-Peloche G, Del Rio B, Vicens-Zygmunt V et al (2025) Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial. Eur Respir J 65(4):2402249. https:\/\/doi.org\/10.1183\/13993003.02249-2024","journal-title":"Eur Respir J"},{"key":"2071_CR5","doi-asserted-by":"publisher","DOI":"10.31083\/FBS28262","author":"OV Blagova","year":"2025","unstructured":"Blagova OV, Kogan EA, Novosadov VM et al (2025) Post-covid versus non-covid myocarditis: comparison of morphological activity, toll-like receptor distribution and responses to immunosuppressive therapy. Front Biosci-Schol. https:\/\/doi.org\/10.31083\/FBS28262","journal-title":"Front Biosci-Schol"},{"issue":"12","key":"2071_CR6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1080\/17474086.2023.2288154","volume":"16","author":"A Boccatonda","year":"2023","unstructured":"Boccatonda A, Campello E, Simion C, Simioni P (2023) Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-COV-2 infection. Expert Rev Hematol 16(12):1035\u20131048. https:\/\/doi.org\/10.1080\/17474086.2023.2288154","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2071_CR7","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2666-5247(20)30172-5","volume":"2","author":"M Cevik","year":"2021","unstructured":"Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A (2021) SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2(1):e13\u2013e22. https:\/\/doi.org\/10.1016\/S2666-5247(20)30172-5","journal-title":"Lancet Microbe"},{"key":"2071_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.866113","author":"S Charfeddine","year":"2022","unstructured":"Charfeddine S, Ibnhadjamor H, Jdidi J, Torjmen S, Kraiem S, Bahloul A, Makni A, Kallel N, Moussa N, Boudaya M, Touil I, Ghrab A, Elghoul J, Meddeb Z, Thabet Y, Ben Salem K, Addad F, Bouslama K, Milouchi S, Hammami R (2022) Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with long-COVID-19: insights from TUN-EndCOV study. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2022.866113","journal-title":"Front Cardiovasc Med"},{"key":"2071_CR9","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.86015","volume":"12","author":"B Chen","year":"2023","unstructured":"Chen B, Julg B, Mohandas S, Bradfute S (2023a) Viral persistence, reactivation, and mechanisms of long COVID. Elife 12:e86015. https:\/\/doi.org\/10.7554\/eLife.86015","journal-title":"Elife"},{"key":"2071_CR10","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.86015","volume":"12","author":"B Chen","year":"2023","unstructured":"Chen B, Julg B, Mohandas S, Bradfute SB (2023b) Viral persistence, reactivation, and mechanisms of long COVID. Elife 12:e86015. https:\/\/doi.org\/10.7554\/eLife.86015","journal-title":"Elife"},{"issue":"3","key":"2071_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/pathophysiology29030039","volume":"29","author":"LP Churilov","year":"2022","unstructured":"Churilov LP, Normatov MG, Utekhin VJ (2022) Molecular mimicry between SARS-CoV-2 and human endocrinocytes: A prerequisite of post-COVID-19 endocrine autoimmunity? Pathophysiology 29(3):486\u2013494. https:\/\/doi.org\/10.3390\/pathophysiology29030039","journal-title":"Pathophysiology"},{"issue":"1","key":"2071_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12016-011-8294-7","volume":"42","author":"MF Cusick","year":"2012","unstructured":"Cusick MF, Libbey JE, Fujinami RS (2012) Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol 42(1):102\u2013111. https:\/\/doi.org\/10.1007\/s12016-011-8294-7","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"2071_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long covid: major findings, mechanisms and recommendations. Nat Rev Microbiol 21(3):133\u2013146. https:\/\/doi.org\/10.1038\/s41579-022-00846-2","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"2071_CR14","doi-asserted-by":"publisher","first-page":"2102930","DOI":"10.1183\/13993003.02930-2021","volume":"59","author":"S Dhooria","year":"2022","unstructured":"Dhooria S, Chaudhary S, Sehgal IS et al (2022) High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial). Eur Respir J 59(2):2102930. https:\/\/doi.org\/10.1183\/13993003.02930-2021","journal-title":"Eur Respir J"},{"key":"2071_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104552","volume":"91","author":"E Esp\u00edn","year":"2023","unstructured":"Esp\u00edn E et al (2023) Cellular and molecular biomarkers of long COVID: a scoping review. EBioMedicine 91:104552. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104552","journal-title":"EBioMedicine"},{"issue":"2","key":"2071_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272472","volume":"18","author":"D Forshaw","year":"2023","unstructured":"Forshaw D et al (2023) STIMULATE-ICP: a pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: a structured protocol. PLoS ONE 18(2):e0272472. https:\/\/doi.org\/10.1371\/journal.pone.0272472","journal-title":"PLoS ONE"},{"issue":"1","key":"2071_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s42466-024-00311-w","volume":"6","author":"C Franke","year":"2024","unstructured":"Franke C, Raeder V, Boesl F et al (2024) Randomized controlled double-blind trial of methylprednisolone versus placebo in patients with post-COVID-19 syndrome and cognitive deficits: study protocol of the post-corona-virus immune treatment (PoCoVIT) trial. Neurol Res Pract 6(1):16. https:\/\/doi.org\/10.1186\/s42466-024-00311-w","journal-title":"Neurol Res Pract"},{"issue":"7","key":"2071_CR18","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s10875-021-01083-7","volume":"41","author":"J Garc\u00eda-Abell\u00e1n","year":"2021","unstructured":"Garc\u00eda-Abell\u00e1n J, Padilla S, Fern\u00e1ndez-Gonz\u00e1lez M et al (2021) Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol 41(7):1490\u20131501. https:\/\/doi.org\/10.1007\/s10875-021-01083-7","journal-title":"J Clin Immunol"},{"key":"2071_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/10760296241297647","author":"AJ Gonzalez-Ochoa","year":"2025","unstructured":"Gonzalez-Ochoa AJ, Szolnoky G, Hernandez-Ibarra AG, Fareed J (2025) Treatment with sulodexide downregulates biomarkers for endothelial dysfunction in convalescent COVID-19 patients. Clin Appl Thromb Hemost. https:\/\/doi.org\/10.1177\/10760296241297647","journal-title":"Clin Appl Thromb Hemost"},{"key":"2071_CR20","doi-asserted-by":"publisher","DOI":"10.36141\/svdld.v40i4.15055","author":"S Gul","year":"2023","unstructured":"Gul S, Demirkol B, Eren R et al (2023) The clinical, functional, and radiological effect of long-term used immunosuppressive therapy for post-COVID-19 interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. https:\/\/doi.org\/10.36141\/svdld.v40i4.15055","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"4","key":"2071_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060413","volume":"12","author":"S Haroon","year":"2022","unstructured":"Haroon S et al (2022) Therapies for long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (the TLC study). BMJ Open 12(4):e060413. https:\/\/doi.org\/10.1136\/bmjopen-2021-060413","journal-title":"BMJ Open"},{"key":"2071_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2024.100733","volume":"36","author":"A Isman","year":"2024","unstructured":"Isman A, Nyquist A, Strecker B et al (2024) Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain Behav Immun Health 36:100733. https:\/\/doi.org\/10.1016\/j.bbih.2024.100733","journal-title":"Brain Behav Immun Health"},{"issue":"19","key":"2071_CR23","doi-asserted-by":"publisher","first-page":"11740","DOI":"10.3390\/ijms231911740","volume":"23","author":"D Jarczak","year":"2022","unstructured":"Jarczak D, Nierhaus A (2022) Cytokine storm\u2014definition, causes, and implications. Int J Mol Sci 23(19):11740. https:\/\/doi.org\/10.3390\/ijms231911740","journal-title":"Int J Mol Sci"},{"key":"2071_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.565665","author":"L Karimi","year":"2020","unstructured":"Karimi L, Sales C, Crewther SG, Wijeratne T (2020) \u2018Acute ischemic stroke in SARS-COV, MERS-COV, SARS-COV-2: neurorehabilitation implications of inflammation induced immunological responses affecting vascular systems. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.565665","journal-title":"Front Neurol"},{"key":"2071_CR25","doi-asserted-by":"publisher","DOI":"10.36141\/svdld.v41i4.15614","author":"B Kerget","year":"2024","unstructured":"Kerget B, G\u00fclbahar BN, \u00c7\u0131nar I et al (2024) Comparison of methotrexate and methylprednisolone as addition to antifibrotic therapy in progressive pulmonary fibrosis due to covid-19. Sarcoidosis Vasc Diffuse Lung Dis. https:\/\/doi.org\/10.36141\/svdld.v41i4.15614","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"3","key":"2071_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3947\/ic.2022.0141","volume":"54","author":"Y Kim","year":"2022","unstructured":"Kim Y, Kim S, Kim T et al (2022) Preliminary guidelines for the clinical evaluation and management of long COVID. Infect Chemother 54(3):566. https:\/\/doi.org\/10.3947\/ic.2022.0141","journal-title":"Infect Chemother"},{"issue":"1","key":"2071_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12863-022-01040-2","volume":"23","author":"BF Koch","year":"2022","unstructured":"Koch BF (2022) SARS-CoV-2 and human retroelements: a case for molecular mimicry? BMC Genom Data 23(1):27. https:\/\/doi.org\/10.1186\/s12863-022-01040-2","journal-title":"BMC Genom Data"},{"key":"2071_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01623-4","author":"A Kruger","year":"2022","unstructured":"Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB et al (2022) Proteomics of fibrin amyloid microclots in long COVID\/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/s12933-022-01623-4","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2071_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmii.2022.10.003","volume":"56","author":"CC Lai","year":"2023","unstructured":"Lai CC, Hsu CK, Yen MY, Lee PI, Ko WC, Hsueh PR (2023a) Long covid: an inevitable sequela of SARS-COV-2 infection. J Microbiol Immunol Infect 56(1):1\u20139. https:\/\/doi.org\/10.1016\/j.jmii.2022.10.003","journal-title":"J Microbiol Immunol Infect"},{"key":"2071_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1085988","volume":"10","author":"YJ Lai","year":"2023","unstructured":"Lai YJ, Liu SH, Manachevakul S et al (2023b) Biomarkers in long COVID-19: a systematic review. Front Med 10:1085988. https:\/\/doi.org\/10.3389\/fmed.2023.1085988","journal-title":"Front Med"},{"issue":"10","key":"2071_CR31","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"W Lee","year":"2020","unstructured":"Lee W, Wheatley A, Kent S, DeKosky B (2020) Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol 5(10):1185\u20131191. https:\/\/doi.org\/10.1038\/s41564-020-00789-5","journal-title":"Nat Microbiol"},{"issue":"5","key":"2071_CR32","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3390\/cells12050816","volume":"12","author":"A Leng","year":"2023","unstructured":"Leng A, Shah M, Ahmad SA et al (2023) Pathogenesis underlying neurological manifestations of long COVID syndrome and potential therapeutics. Cells 12(5):816. https:\/\/doi.org\/10.3390\/cells12050816","journal-title":"Cells"},{"issue":"6","key":"2071_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li G, Hilgenfeld R, Whitley R, De Clercq E (2023) Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov 22(6):449\u2013475. https:\/\/doi.org\/10.1038\/s41573-023-00672-y","journal-title":"Nat Rev Drug Discov"},{"issue":"33","key":"2071_CR34","doi-asserted-by":"publisher","first-page":"12578","DOI":"10.1080\/10408398.2022.2103090","volume":"63","author":"S Liu","year":"2023","unstructured":"Liu S, Zhao Y, Feng X, Xu H (2023) SARS-CoV-2 infection threatening intestinal health: a review of potential mechanisms and treatment strategies. Crit Rev Food Sci Nutr 63(33):12578\u201312596. https:\/\/doi.org\/10.1080\/10408398.2022.2103090","journal-title":"Crit Rev Food Sci Nutr"},{"key":"2071_CR35","doi-asserted-by":"publisher","first-page":"1011936","DOI":"10.3389\/fmed.2023.1011936","volume":"10","author":"RN Low","year":"2023","unstructured":"Low RN, Low RJ, Akrami A (2023) A review of cytokine-based pathophysiology of long COVID symptoms. Front Med 10:1011936. https:\/\/doi.org\/10.3389\/fmed.2023.1011936","journal-title":"Front Med"},{"issue":"5","key":"2071_CR36","doi-asserted-by":"publisher","first-page":"e01987","DOI":"10.1128\/mBio.01987-21","volume":"12","author":"T Maemura","year":"2021","unstructured":"Maemura T, Kuroda M, Armbrust T et al (2021) Antibody-dependent enhancement of SARS-CoV-2 infection is mediated by the IgG receptors Fc\u03b3RIIA and Fc\u03b3RIIIA but does not contribute to aberrant cytokine production by macrophages. Mbio 12(5):e01987-e2021. https:\/\/doi.org\/10.1128\/mBio.01987-21","journal-title":"Mbio"},{"issue":"6585","key":"2071_CR37","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1126\/science.abm8108","volume":"375","author":"M Merad","year":"2022","unstructured":"Merad M, Blish CA, Sallusto F, Iwasaki A (2022) The immunology and immunopathology of COVID-19. Science 375(6585):1122\u20131127. https:\/\/doi.org\/10.1126\/science.abm8108","journal-title":"Science"},{"issue":"5","key":"2071_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-085272","volume":"14","author":"H Naik","year":"2024","unstructured":"Naik H, Cooke E, Boulter T et al (2024) Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia. BMJ Open 14(5):e085272. https:\/\/doi.org\/10.1136\/bmjopen-2024-085272","journal-title":"BMJ Open"},{"key":"2071_CR39","unstructured":"National Heart Lung and Blood Institute (2024) Long covid, National Heart Lung and Blood Institute. Available at: https:\/\/www.nhlbi.nih.gov\/covid\/long-covid."},{"key":"2071_CR40","unstructured":"National Institute for Health and Care Excellence (2020) NICE guidance. Available at: https:\/\/www.nice.org.uk\/guidance\/ng188\/chapter\/5-Management."},{"issue":"712","key":"2071_CR41","doi-asserted-by":"publisher","first-page":"e815","DOI":"10.3399\/BJGP.2021.0265","volume":"71","author":"M Nurek","year":"2021","unstructured":"Nurek M, Rayner C, Freyer A et al (2021) Recommendations for the recognition, diagnosis, and management of long COVID: a Delphi study. Br J Gen Pract 71(712):e815\u2013e825. https:\/\/doi.org\/10.3399\/BJGP.2021.0265","journal-title":"Br J Gen Pract"},{"key":"2071_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100485","volume":"24","author":"B O\u2019Kelly","year":"2022","unstructured":"O\u2019Kelly B, Vidal L, McHugh T et al (2022) Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health 24:100485. https:\/\/doi.org\/10.1016\/j.bbih.2022.100485","journal-title":"Brain Behav Immun Health"},{"key":"2071_CR43","unstructured":"Ocejo, A. (2024) Methylprednisolone, StatPearls [Internet]. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544340\/"},{"issue":"2","key":"2071_CR44","doi-asserted-by":"publisher","first-page":"e01553","DOI":"10.1128\/spectrum.01553-21","volume":"10","author":"K Okuya","year":"2022","unstructured":"Okuya K, Hattori T, Saito T et al (2022) Multiple routes of antibody-dependent enhancement of SARS-CoV-2 infection. Microbiol Spectr 10(2):e01553-e1621. https:\/\/doi.org\/10.1128\/spectrum.01553-21","journal-title":"Microbiol Spectr"},{"key":"2071_CR45","doi-asserted-by":"publisher","DOI":"10.5409\/wjcp.v13.i2.92813","author":"\u00d6 \u00d6zdemir","year":"2024","unstructured":"\u00d6zdemir \u00d6, Kas\u0131mo\u011flu G, Bak A et al (2024) Mast cell activation syndrome: an up-to-date review of literature. World J Clin Pediatrics. https:\/\/doi.org\/10.5409\/wjcp.v13.i2.92813","journal-title":"World J Clin Pediatrics"},{"issue":"12","key":"2071_CR46","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.jcmg.2020.10.005","volume":"13","author":"D Phelan","year":"2020","unstructured":"Phelan D, Kim J, Elliott M et al (2020) Screening of potential cardiac involvement in competitive athletes recovering from COVID-19. JACC Cardiovasc Imaging 13(12):2635\u20132652. https:\/\/doi.org\/10.1016\/j.jcmg.2020.10.005","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2071_CR47","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41590-021-01113-x","volume":"23","author":"C Phetsouphanh","year":"2022","unstructured":"Phetsouphanh C, Darley DR, Wilson DB et al (2022) Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 23(2):210\u2013216. https:\/\/doi.org\/10.1038\/s41590-021-01113-x","journal-title":"Nat Immunol"},{"key":"2071_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01579-5","author":"E Pretorius","year":"2022","unstructured":"Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR et al (2022) Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with long COVID\/post-acute sequelae of covid-19 (PASC). Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/s12933-022-01579-5","journal-title":"Cardiovasc Diabetol"},{"key":"2071_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.698169","volume":"12","author":"AD Proal","year":"2021","unstructured":"Proal AD, VanElzakker MB (2021) Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol 12:698169. https:\/\/doi.org\/10.3389\/fmicb.2021.698169","journal-title":"Front Microbiol"},{"key":"2071_CR50","unstructured":"Puckett Y (2025) Prednisone, StatPearls [Internet]. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534809\/. Accessed 23 July 2025"},{"issue":"1","key":"2071_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocmr.2024.101121","volume":"27","author":"VO Puntmann","year":"2025","unstructured":"Puntmann VO, Beitzke D, Kammerlander A et al (2025) Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inflammatory heart disease using cardiovascular magnetic resonance endpoints. J Cardiovasc Magn Reson 27(1):101121. https:\/\/doi.org\/10.1016\/j.jocmr.2024.101121","journal-title":"J Cardiovasc Magn Reson"},{"issue":"10","key":"2071_CR52","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.apmr.2021.03.035","volume":"102","author":"S Reina-Guti\u00e9rrez","year":"2021","unstructured":"Reina-Guti\u00e9rrez S, Torres-Costoso A, Mart\u00ednez-Vizca\u00edno V et al (2021) Effectiveness of pulmonary rehabilitation in interstitial lung disease, including coronavirus diseases: a systematic review and meta-analysis. Arch Phys Med Rehabil 102(10):1989-1997.e3. https:\/\/doi.org\/10.1016\/j.apmr.2021.03.035","journal-title":"Arch Phys Med Rehabil"},{"key":"2071_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107362","volume":"217","author":"RHA Sansores","year":"2023","unstructured":"Sansores RHA, Ram\u00edrez-Venegas F, Montiel-Lopez S et al (2023) \u2018Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy. Respiratory Med 217:107362. https:\/\/doi.org\/10.1016\/j.rmed.2023.107362","journal-title":"Respiratory Med"},{"key":"2071_CR54","doi-asserted-by":"publisher","first-page":"1582967","DOI":"10.3389\/fmolb.2025.1582967","volume":"12","author":"EM Sasso","year":"2025","unstructured":"Sasso EM, Eaton-Fitch N, Smith P et al (2025) Low-dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients. Front Mol Biosci 12:1582967. https:\/\/doi.org\/10.3389\/fmolb.2025.1582967","journal-title":"Front Mol Biosci"},{"issue":"8","key":"2071_CR55","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.3390\/ijerph18084350","volume":"18","author":"A Sis\u00f3-Almirall","year":"2021","unstructured":"Sis\u00f3-Almirall A, Brito-Zer\u00f3n P, Conangla Ferr\u00edn L et al (2021) Long Covid-19: proposed primary care clinical guidelines for diagnosis and disease management. Int J Environ Res Public Health 18(8):4350. https:\/\/doi.org\/10.3390\/ijerph18084350","journal-title":"Int J Environ Res Public Health"},{"key":"2071_CR56","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.0000000000000022","author":"S Sumantri","year":"2023","unstructured":"Sumantri S, Rengganis I (2023) Immunological dysfunction and mast cell activation syndrome in long COVID. Asia Pac Allergy. https:\/\/doi.org\/10.5415\/apallergy.0000000000000022","journal-title":"Asia Pac Allergy"},{"issue":"2","key":"2071_CR57","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10787-023-01194-0","volume":"31","author":"S Szabo","year":"2023","unstructured":"Szabo S, Zayachkivska O, Hussain A, Muller L (2023) What is really \u201clong covid.\u201d Inflammopharmacology 31(2):551\u2013557. https:\/\/doi.org\/10.1007\/s10787-023-01194-0","journal-title":"Inflammopharmacology"},{"key":"2071_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08925-2","author":"C Tengelmann","year":"2024","unstructured":"Tengelmann C, Joos S, Kau\u00dfner Y et al (2024) Feasibility, safety and effectiveness of prednisolone and vitamin B1, B6, and B12 in patients with post-COVID-19-syndrome (previtacov) \u2013 protocol of a randomised, double-blind, placebo-controlled multicentre trial in primary care (phase iiib). BMC Infect Dis. https:\/\/doi.org\/10.1186\/s12879-023-08925-2","journal-title":"BMC Infect Dis"},{"key":"2071_CR59","unstructured":"Turkish Thoracic Society (2023) Systemic corticosteroids in treatment of post-COVID-19 interstitial lung disease (STERCOV-ILD). ClinicalTrials.gov (NCT04988282). Available at: https:\/\/clinicaltrials.gov\/study\/NCT04988282. Accessed 24 July 2025"},{"issue":"4","key":"2071_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/pzac005","volume":"102","author":"R Twomey","year":"2022","unstructured":"Twomey R, Demars J, Franklin K et al (2022) Chronic fatigue and postexertional malaise in people living with long COVID: an observational study. Phys Ther 102(4):pzac005. https:\/\/doi.org\/10.1093\/ptj\/pzac005","journal-title":"Phys Ther"},{"issue":"3","key":"2071_CR61","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/bloodadvances.2020003968","volume":"5","author":"FA von Meijenfeldt","year":"2021","unstructured":"von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundstr\u00f6m A, Magnusson M, Mackman N et al (2021) Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv 5(3):756\u2013759. https:\/\/doi.org\/10.1182\/bloodadvances.2020003968","journal-title":"Blood Adv"},{"key":"2071_CR62","unstructured":"World Health Organization (2021) A clinical case definition of post covid-19 condition by a Delphi Consensus, 6 October 2021. World Health Organization. Available at: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1."},{"key":"2071_CR63","doi-asserted-by":"publisher","unstructured":"Y\u00fcksel A, Karado\u011fan D, H\u00fcrsoy N et al (2022) Methylprednisolone in the treatment of post-COVID-19 Interstitial Lung Disease (STERCOV-ILD). In: 12.02 - ILD\/DPLD of known origin. ERS International Congress 2022 abstracts, European Respiratory Society. pp 3404. https:\/\/doi.org\/10.1183\/13993003.congress-2022.3404","DOI":"10.1183\/13993003.congress-2022.3404"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02071-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02071-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02071-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:12:48Z","timestamp":1771636368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02071-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2071"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02071-8","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}